NEKTAR THERAPEUTICS NKTR

Healthcare

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.

NDAQ:NKTR - Post by User

NEKTAR THERAPEUTICS

Bullboard Posts

Post by coolfooldumbguyon Jan 15, 2020 10:57am

80 Views

Post# 30555443

watching this one for

a possible purchase in the low $21 range,was on my watchlist last spring,but its low is past and a rebound seems to be at work here,so glta shareholders.

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market